Compare Liquidia Corporation Common Stock (LQDA) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs Strategy Inc. — how do they compare? Liquidia Corporation Common Stock trades at $34.17 (market cap $2.40B), while Strategy Inc. trades at $140.91 (market cap $64.44B). The key difference: Strategy Inc. is far larger — about 26.9× Liquidia Corporation Common Stock's market cap, and Strategy Inc. is more actively traded (12,273,653 versus 2,857,547). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Strategy Inc. for 113 Days on average.
| LQDA | MSTR | |
|---|---|---|
Market Cap | $2.40B | $64.44B |
Volume | 2,857,547 | 12,273,653 |
Sector | Health | Technology |
52-Week High | $91.03 | $301.91 |
52-Week Low | $22.02 | $82.31 |
Typical Hold Time | 0 Days | 113 Days |
Enterprise Value | $2.30B | $83.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.
The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
